Organization Profile

You just read:

NEOMED Institute Launches NEOMED Therapeutics 1 Inc. to fund and develop a dual BET inhibitor anticancer therapy pipeline with NEO2734, an oral dual BET and CBP/P300 inhibitor, as lead compound

News provided by

NEOMED

Feb 28, 2018, 13:10 ET